Oncology and Hematology

Episodes 97-112 of 463

Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
Global Oncology Academy
Clinical Decision-Making in Metastatic Breast Cancer: Optimizing Sequencing Choices
- Ashley Baker, MSN, PMHNP
- Giancarlo Moscol, M.D.
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
MinuteCE®
Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
Global Oncology Academy
Improving Metastatic Breast Cancer Care Through Integrated Palliative Support
- Ryan Quigley
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
- Namrata Vijayvergia, MD
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Project Oncology®
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Project Oncology®
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
- Charles Turck, PharmD, BCPS, BCCCP
- Manali Kamdar, MD
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Clinician's Roundtable
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
- Charles Turck, PharmD, BCPS, BCCCP
- Brennan Spiegel, MD, MSHS